JP2019532635A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532635A5 JP2019532635A5 JP2019515539A JP2019515539A JP2019532635A5 JP 2019532635 A5 JP2019532635 A5 JP 2019532635A5 JP 2019515539 A JP2019515539 A JP 2019515539A JP 2019515539 A JP2019515539 A JP 2019515539A JP 2019532635 A5 JP2019532635 A5 JP 2019532635A5
- Authority
- JP
- Japan
- Prior art keywords
- msc
- ido
- composition
- oncolytic virus
- infected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000958041 Homo sapiens Musculin Proteins 0.000 claims 40
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 23
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 13
- 239000003112 inhibitor Substances 0.000 claims 12
- 244000309459 oncolytic virus Species 0.000 claims 11
- 241000725643 Respiratory syncytial virus Species 0.000 claims 6
- 230000002269 spontaneous effect Effects 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 230000006907 apoptotic process Effects 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000002950 deficient Effects 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000007812 deficiency Effects 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 108091033409 CRISPR Proteins 0.000 claims 2
- 238000010354 CRISPR gene editing Methods 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 102000046949 human MSC Human genes 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 230000002934 lysing effect Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000000174 oncolytic effect Effects 0.000 claims 2
- 229940023041 peptide vaccine Drugs 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical class C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 claims 1
- 102000016680 Dioxygenases Human genes 0.000 claims 1
- 108010028143 Dioxygenases Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662396604P | 2016-09-19 | 2016-09-19 | |
| US62/396,604 | 2016-09-19 | ||
| PCT/US2017/052313 WO2018053529A1 (en) | 2016-09-19 | 2017-09-19 | Method of targeting oncolytic viruses to tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532635A JP2019532635A (ja) | 2019-11-14 |
| JP2019532635A5 true JP2019532635A5 (enExample) | 2020-10-15 |
| JP7358236B2 JP7358236B2 (ja) | 2023-10-10 |
Family
ID=61619005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515539A Active JP7358236B2 (ja) | 2016-09-19 | 2017-09-19 | 腫瘍溶解性ウイルスを腫瘍に標的化する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11607426B2 (enExample) |
| EP (2) | EP4268838A3 (enExample) |
| JP (1) | JP7358236B2 (enExample) |
| CA (1) | CA3037333A1 (enExample) |
| WO (1) | WO2018053529A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018372631B2 (en) | 2017-11-22 | 2025-06-05 | Mesoblast International Sarl | Cellular compositions and methods of treatment I |
| AU2020325825A1 (en) * | 2019-08-05 | 2022-03-17 | Mesoblast International Sarl | Cellular compositions comprising viral vectors and methods of treatment |
| KR102233568B1 (ko) * | 2019-12-13 | 2021-03-30 | 주식회사 알바이오 | 항암 바이러스가 도입된 중간엽 줄기세포의 세포 생존능을 향상시키는 방법 |
| US20230293590A1 (en) * | 2020-08-10 | 2023-09-21 | Mesoblast International Sárl | Cellular compositions and methods of treatment |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006122150A1 (en) | 2005-05-10 | 2006-11-16 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
| US8685728B2 (en) * | 2008-01-31 | 2014-04-01 | Rutgers The State University Of New Jersey | Kit containing stem cells and cytokines for use in attenuating immune responses |
| CN102083429B (zh) | 2008-04-24 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
| KR101847107B1 (ko) | 2008-07-08 | 2018-04-10 | 인사이트 홀딩스 코포레이션 | 인돌아민 ２,３-디옥시게나아제의 억제제로서의 １,２,５-옥사디아졸 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| US8597637B1 (en) * | 2010-05-18 | 2013-12-03 | Weidong Zhang | Breast cancer therapy using an engineered respiratory syncytial virus |
| KR102353601B1 (ko) * | 2012-12-14 | 2022-01-19 | 럿거스, 더 스테이트 유니버시티 오브 뉴저지 | 줄기세포의 면역조절성 효과의 조절 방법 |
| WO2014160475A1 (en) | 2013-03-13 | 2014-10-02 | Aboody Karen S | Tropic cell based virotherapy for the treatment of cancer |
| RU2667509C2 (ru) | 2013-03-14 | 2018-09-21 | Ньюлинк Джинетикс Корпорейшин | Трициклические соединения в качестве ингибиторов иммуносупрессии, опосредуемой метаболизированием триптофана |
| US20160303174A1 (en) * | 2013-12-11 | 2016-10-20 | The General Hospital Corporation | Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors |
-
2017
- 2017-09-19 CA CA3037333A patent/CA3037333A1/en active Pending
- 2017-09-19 EP EP23172956.7A patent/EP4268838A3/en active Pending
- 2017-09-19 JP JP2019515539A patent/JP7358236B2/ja active Active
- 2017-09-19 WO PCT/US2017/052313 patent/WO2018053529A1/en not_active Ceased
- 2017-09-19 EP EP17851803.1A patent/EP3515462B1/en active Active
- 2017-09-19 US US16/330,858 patent/US11607426B2/en active Active
-
2023
- 2023-03-20 US US18/186,869 patent/US20230364147A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Merten et al. | Viral vectors for gene therapy and gene modification approaches | |
| CN106659777A8 (zh) | 免疫原性组合产品 | |
| JP2019532635A5 (enExample) | ||
| WO2019040920A8 (en) | PREPARATION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS | |
| HRP20180282T1 (hr) | Imunoterapija na bazi indoleamin 2, 3-dioksigenaze | |
| WO2020028751A3 (en) | Aav variants with enhanced tropism | |
| EA201892648A1 (ru) | Вирусы пичинде с трехсегментным геномом в качестве векторных вакцин | |
| JP2015524462A5 (enExample) | ||
| BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
| JP2012136541A5 (enExample) | ||
| EP3266464A3 (en) | Yeast-based therapeutic for chronic hepatitis b infection | |
| JP2016535009A5 (enExample) | ||
| JP2011528896A5 (enExample) | ||
| MX2020000221A (es) | Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas. | |
| WO2008103380A3 (en) | Hepatitis b virus compositions and methods of use | |
| JP2014502156A5 (enExample) | ||
| WO2014205579A4 (en) | Modified matrix proteins of vesicular stomatitis virus | |
| BR112019005511A2 (pt) | vetores de adenovírus canino | |
| JP2016531927A5 (enExample) | ||
| MX382985B (es) | Nuevos virus de tilapia y sus usos | |
| JP2016529223A5 (enExample) | ||
| IN2015DN02546A (enExample) | ||
| JP2011528897A5 (enExample) | ||
| JP2016513471A5 (enExample) | ||
| RU2019113989A (ru) | Лекарственное средство |